AI for Scientific Discovery Market Revenue to Attain USD 34.78 Bn by 2035

Published: 09 Mar 2026

Author: Precedence Research

Share:

AI for Scientific Discovery Market Revenue and Trends 2026 to 2035

The global AI for scientific discovery market revenue was valued at USD 4.80 billion in 2025 and is expected to attain around USD 34.78 billion by 2035, growing at a CAGR of 21.90% during the forecast period. This market is experiencing unprecedented growth, driven by the growing demand from the pharmaceutical industry and rising adoption of cloud-based platforms for analyzing complex data, simulating experiments, and shortening development timelines.

What are the Factors Contributing to the Growth of the AI for Scientific Discovery Market?

The increasing use of generative AI for drug discovery is the major driver, accelerating the growth of the AI for scientific discovery market. AI finds various applications in drug discovery, including the identification of new drug candidates, molecular screening, and de novo design. AI models are widely used to analyze diverse data types, including images, text, and numerical data, significantly improving the accuracy of scientific predictions.

Segment Insights:

• By offering, the AI software platforms segment held a dominant market share of approximately 44% in 2025, owing to the growing need to find drug candidates and manage massive datasets in drug discovery. AI software predicts the effectiveness of compounds before laboratory testing, which improves the success rates of early-stage trials.
• By technology, the machine learning algorithms segment accounted for the highest revenue share of nearly 36% in 2025. Machine Learning (ML) automates time-consuming and repetitive tasks, allowing researchers to focus on complex problems. ML algorithms can efficiently analyze millions of molecular structures to identify promising drug candidates, accelerating the research and drug discovery process.
• By application, the drug discovery and biomedical research segment contributed the biggest market share of approximately 34% in 2025, driven by AI’s ability to process complex datasets and solve intricate scientific problems. AI is enabling more cost-effective drug development. 
• By end user, the pharmaceutical and biotechnology companies segment registered its dominance, holding nearly 36% share in 2025. Pharmaceutical and biotechnology companies are the major end users in the market. These companies heavily invest in R&D activities, which encourages them to adopt AI technologies to reduce frequent failure rates, optimize clinical trials, and analyze massive biological datasets. 

Regional Insights:

North America holds the dominant position in the global AI for scientific discovery market. The region strongly benefits from the well-established healthcare infrastructure and strategic collaborations between leading pharmaceutical companies and AI solution providers. The region is home to many leading market players, including Amazon Web Services Inc., Atomwise Inc., Benchling Inc., Generate Biomedicines, Google LLC, IBM Corp., Microsoft Corp., NVIDIA Corp., Recursion Pharmaceuticals Inc., Schrodinger Inc., and others. 

The U.S. is the major contributor to the North American market, owing to the presence of well-established research institutions and rising private-sector investments in AI-driven scientific research. The area’s leadership is driven by the rising burden of chronic diseases, extensive R&D integration across scientific sectors, and rising adoption of AI-integrated quantum computing and blockchain. Moreover, the rising integration of cloud computing is being used to manage high-volume AI-generated data and extract valuable insights.

On the other hand, Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period. The fastest growth of the region is attributed to the rising adoption of AI technologies, the rising prevalence of chronic diseases, the rising integration of cloud computing, significant investment in R&D by pharmaceuticals and biotechnology companies, and a favorable government framework for AI-enabled research platforms.

AI for Scientific Discovery Market Coverage

Recent Development:

• In February 2026, Merck and Mayo Clinic announced a research and development agreement to apply artificial intelligence (AI), advanced analytics, and multimodal clinical data to support drug discovery and development. The agreement integrates Mayo Clinic's Platform architecture as well as clinical and genomic datasets with Merck's ambition to harness AI-enabled virtual cell technologies to enhance disease understanding, improve target identification, and drive early development decisions.
  https://newsnetwork.mayoclinic.org/discussion/merck-and-mayo-clinic-announce-new-research-and-development-collaboration-to-support-ai-enabled-drug-discovery-and-precision-medicine/

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/checkout/7938

You can place an order or ask any questions. Please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344